NCT00100087Unknown1 期
A Safety and Feasibility Study of the TheraSight(TM) Ocular Brachytherapy System for Treatment of Age-Related Macular Degeneration
适应症
试验速览
- 阶段
- 1 期
- 入组人数
- 30
- 试验地点
- 6
- 主要终点
- Incidence of serious adverse events 30 to 270 days after treatment
研究概览
简要总结
The study will investigate the safety and feasibility of using the TheraSight(TM) Brachytherapy System for treatment of wet age-related macular degeneration (AMD).
详细描述
This is a multi-center randomized study of three doses of radiation (assigned 1:1:1) delivered by the TheraSight(TM) Brachytherapy System in participants with choroidal neovascularization (CNV) secondary to wet (exudative) AMD. Each participant receives a single dose of radiation delivered by one-time only brachytherapy. Participants are followed for three years after the radiation treatment.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 50 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age 50 years or older.
- •Active primary or recurrent subfoveal CNV secondary to AMD with minimally classic or occult lesion, where an active lesion is defined as one or more of the following:
- •a) An increase > 10% in lesion size (greatest linear dimension) on screening fluorescein angiography compared to previous fluorescein angiography no more than 180 days preceding screening visit
- •b) Subretinal hemorrhage associated with CNV within 90 days of screening visit.
- •c) Visual acuity loss > 1 Snellen line in screening visual acuity compared to previous visual acuity no more than 180 days preceding screening
- •Lesion < 6 mm greatest linear dimension (GLD)
- •Submacular blood must comprise less than 75% of the total lesion
- •Subretinal fibrosis must comprise less than 25% of the total lesion
- •Study eye best-corrected vision of 20/100 or poorer measured on an ETDRS chart (< 48 letters correct)
- •Fellow eye best-corrected vision that is at least one line better on an ETDRS chart than the best-corrected vision of the study eye
- •HbA1c < 6%
- •Read and signed informed consent
排除标准
- •Prior AMD therapy treatment, including but not limited to laser and photodynamic therapy.
- •Current or planned participation in the next 180 days in other experimental trials involving treatment of neovascular AMD in the study eye, ocular devices, or trials involving treatment for ocular conditions other than AMD.
- •Prior ophthalmic surgery for the study eye other than cataract extraction and/or capsulotomy. A minimum interval of 180 days must elapse between cataract extraction or capsulotomy and study enrollment.
- •Likely need for cataract surgery in study eye during the 180 days following TheraSight(TM) System treatment.
- •Presence of other eye diseases that could compromise visual acuity in the study eye or that, in the clinical judgment of the evaluating study ophthalmologist, might create special risk for the study participant.
- •CNV due to other causes such as ocular histoplasmosis or pathologic myopia.
- •Endstage fibrotic disciform lesions.
- •Diabetes requiring diet modification, or medication, or insulin.
- •Current history of malignancy (except participants having basal cell carcinoma that was treated successfully, or other malignancy operated on or treated and in remission for five years prior to inclusion in the trial).
- •Hypertensive retinopathy.
- •Major cardiovascular or cerebrovascular event within the last year; examples include congestive heart failure, myocardial infarction, and stroke.
- •Inability to complete follow-up.
- •Allergy to fluorescein dye.
- •Previous radiation to the study eye.
- •Pregnancy at time of surgical procedure.
结局指标
主要结局
Incidence of serious adverse events 30 to 270 days after treatment
次要结局
- Serious adverse events occurring 9 months to 3 years after treatment
- Reported adverse events occurring at any time after treatment
- Feasibility of device use based on physician interviews and ultrasonography
- Observation of retinal and angiographic appearance of CNV lesion and best-corrected visual acuity
研究者
研究点 (6)
Loading locations...
相似试验
已完成
不适用
Evaluation of the Treatment of Adipose Tissue With Liposonix System (Model 2) Using a New Treatment MethodSubcutaneous Adipose TissueNCT01853397Solta Medical72
Unknown
1 期
Safety & Tolerability of the IRay System in Subjects With Exudative Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD)Wet Age-Related Macular DegenerationEye DiseasesRetinal DiseasesMacular DegenerationAge-Related Macular DegenerationNCT01217762Oraya Therapeutics, Inc.62
已完成
1 期
A Feasibility Study to Evaluate Safety and Initial Effectiveness of ExAblate Transcranial MR Guided Focused Ultrasound for Unilateral Pallidotomy in the Treatment of Dyskinesia of Parkinson's DiseaseLevodopa Induced Dyskinesia in Patients With Parkinson's DiseaseNCT02003248Yonsei University10
已完成
不适用
A Study on Safety of tDCS One-shot in UCPHemiplegic Cerebral PalsyNCT03137940IRCCS Fondazione Stella Maris8
Unknown
不适用
Single Application Brachytherapy in Cervical CancerCervical CancerNCT03110497Tata Memorial Hospital40